Global Clinical Updates

A major milestone has been reached for Australians living with arthritis and musculoskeletal conditions, with the Australian Government announcing a new $100 million Medical Research Future Fund (MRFF) Mission dedicated to arthritis and musculoskeletal health. Nearly seven million Australians are affected by these conditions, including many people living with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). This landmark investment recognises the significant impac

New results presented at the EULAR 2026 Congress suggest that baricitinib may help people with newly diagnosed polymyalgia rheumatica achieve remission while substantially reducing their reliance on glucocorticoids. In the Phase 3 JAK-SPARE trial, nearly two-thirds of patients receiving baricitinib achieved glucocorticoid-free remission within 16 weeks, compared with fewer than one in five patients receiving placebo. Patients treated with baricitinib also required significant

The European Alliance of Associations for Rheumatology (EULAR) has released updated international recommendations for the diagnosis and management of polymyalgia rheumatica (PMR) and large vessel vasculitis, including giant cell arteritis (GCA). Developed by an international expert task force representing 13 countries, the recommendations place a strong emphasis on early specialist assessment, accurate diagnosis using imaging and other objective tests, and shared decision-mak

A major international clinical trial published in The New England Journal of Medicine has shown that secukinumab can significantly improve outcomes for people with relapsing polymyalgia rheumatica (PMR). The Phase 3 REPLENISH trial found that patients receiving secukinumab alongside a structured steroid taper were approximately twice as likely to achieve sustained remission after one year compared with patients receiving standard treatment alone. We were proud to have recruit